Skip to content
Screener

ArriVent BioPharma, Inc. AVBP Total Liabilities & Equity

Total Liabilities & Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$436.76M+79.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$472.67M-26.2%
Nuvation Bio logo
Nuvation BioNUVB
$744.5M+15.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$553.6M+15.8%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.44B+106%
Enterprise value$1.38B+135%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-058650
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock $0.0001 par value, 200,000,000 shares authorized; 45,308,941 and 42,452,251 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively54
Additional paid-in capital772,206711,847
Accumulated deficit(447,961)(404,641)
Accumulated other comprehensive income (loss)(270)14
Total stockholders’ equity323,980307,224
Total liabilities and stockholders’ equity$349,295$333,169

Item 1. Condensed Financial Statements (Unaudited):

FAQ

What is ArriVent BioPharma, Inc.'s total liabilities & equity?
ArriVent BioPharma, Inc. (AVBP) reported total liabilities & equity of $349.3M in Q1 2026.
How has ArriVent BioPharma, Inc.'s total liabilities & equity changed year-over-year?
ArriVent BioPharma, Inc.'s total liabilities & equity increased by 62.1% year-over-year, from $215.5M to $349.3M.
What is the long-term trend for ArriVent BioPharma, Inc.'s total liabilities & equity?
Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total liabilities & equity has grown at a 42.9% compound annual growth rate (CAGR), from $163.1M to $333.17M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about ArriVent BioPharma, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude